Maura N Dickler

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
    Maura N Dickler
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 115:115-21. 2009
  2. pmc A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Maura N Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:7878-83. 2008
  3. ncbi request reprint Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
    Maura Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:498-9. 2005
  4. doi request reprint Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:628-33. 2010
  5. doi request reprint Bevacizumab for advanced breast cancer
    Shari B Goldfarb
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Womens Health (Lond Engl) 6:17-25. 2010
  6. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
  7. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
  8. doi request reprint Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging
    Valencia King
    Department of Radiology, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Radiology 264:670-8. 2012
  9. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
  10. ncbi request reprint Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004

Detail Information

Publications22

  1. doi request reprint Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
    Maura N Dickler
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 115:115-21. 2009
    ..Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival...
  2. pmc A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Maura N Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:7878-83. 2008
    ..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
  3. ncbi request reprint Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
    Maura Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:498-9. 2005
  4. doi request reprint Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:628-33. 2010
    ..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)...
  5. doi request reprint Bevacizumab for advanced breast cancer
    Shari B Goldfarb
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Womens Health (Lond Engl) 6:17-25. 2010
    ..This review article discusses the clinical trials establishing the use of bevacizumab for the treatment of advanced breast cancer...
  6. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  7. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
    ..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
  8. doi request reprint Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging
    Valencia King
    Department of Radiology, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Radiology 264:670-8. 2012
    ....
  9. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
    ..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
  10. ncbi request reprint Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004
    ....
  11. ncbi request reprint Aromatase inhibitors for hormonal therapy of early-stage breast cancer
    Tiffany A Traina
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Medicine Service, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Investig Drugs 5:605-10. 2004
    ..This review focuses on data on aromatase inhibitors in the adjuvant setting and looks to the future potential of these drugs in both ductal carcinoma in situ and chemoprevention...
  12. ncbi request reprint Biomarkers in breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Biol Ther 7:21-2. 2008
  13. pmc Characteristics of oral mucosal events related to bevacizumab treatment
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Oncologist 17:274-8. 2012
    ..We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab...
  14. pmc Bevacizumab in metastatic breast cancer: when may it be used?
    Shari B Goldfarb
    Memorial Sloan Kettering Cancer Center, Medicine and Epidemiology and Biostatistics, New York, NY, USA
    Ther Adv Med Oncol 3:85-93. 2011
    ..In this article we review the clinical trials testing the utility of bevacizumab for the treatment of metastatic disease...
  15. pmc Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Bryan P Schneider
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:4672-8. 2008
    ..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer...
  16. doi request reprint The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
    J Clin Oncol 26:1216-22. 2008
    ..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival...
  17. ncbi request reprint Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  18. ncbi request reprint Bevacizumab for advanced breast cancer
    Tiffany A Traina
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:303-19. 2007
    ..In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer...
  19. ncbi request reprint Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21
    Teresa A Gilewski
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:2977-85. 2007
    ..To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21...
  20. ncbi request reprint A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
    ..Breast cancer has variable expression of KIT and PDGFR therefore we conducted a phase II trial to evaluate the safety and efficacy of imatinib in patients with metastatic breast cancer (MBC)...
  21. ncbi request reprint Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, IN, USA
    J Clin Oncol 23:792-9. 2005
    ....
  22. ncbi request reprint Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...